Please ensure Javascript is enabled for purposes of website accessibility

Why Was Novavax Awarded Almost $2 Billion in Free Money?

By Taylor Carmichael - Jul 22, 2020 at 7:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Operation Warp Speed (OWS) and the Coalition for Epidemic Preparedness Innovations (CEPI) both selected Novavax for their highest grant awards.

The Coalition for Epidemic Preparedness Innovations (CEPI) was established in 2017 to fund vaccine efforts to stop worldwide epidemics. Co-founded by Bill Gates, the nonprofit is the largest vaccine initiative charity in the world. In May, CEPI made headlines when it granted its largest award ever, $388 million, to tiny Novavax (NVAX 2.80%) to help the biotech develop a vaccine candidate for COVID-19.

Operation Warp Speed (OWS) was created after COVID-19 became a health emergency in the U.S. The idea was to fund multiple vaccine candidates and speed up the drug development process to create a working vaccine as fast as possible. In June, OWS narrowed its favorite vaccine candidates down to five companies: Moderna (MRNA -0.37%), Merck (MRK 2.35%)Pfizer (PFE 3.77%), Johnson & Johnson (JNJ -1.10%), and AstraZeneca (AZN 3.08%). But in July, OWS shocked the world by instead granting $1.6 billion in funding to tiny Novavax.

While other companies have received significant funding from OWS and CEPI, by far the most money was given to one of the smallest players. Why?

Several medicine vials with labels that say "Vaccine nCoV"

Image source: Getty Images

Cinderella needs a little help

In a report published July 16, The New York Times suggested that Novavax won the grants because of the company's close ties with health officials. An anonymous source told the newspaper that small biotech companies need more money than larger pharmaceutical companies to help with manufacturing costs.

While that's obviously true, it doesn't answer the question of why Novavax. After all, many small biotech companies are pursuing a coronavirus vaccine. Most of them haven't been awarded any funding at all. And the federal government's first round of funding skipped Novavax altogether.

While large pharmaceutical companies don't need financial help from the government, they certainly appreciate it. In the first round of funding, OWS named several large pharmaceutical companies (Johnson & Johnson, Merck, Pfizer) and even a foreign company (AstraZeneca) as some of the companies that would get federal funding. Only midsized Moderna would seem to qualify as a Cinderella who might need a little help.

So what changed for Novavax? Why did this small cap emerge from obscurity and receive such a large check from the federal government?

Novavax's vaccine candidate has produced a huge number of antibodies in nonhuman primates

The decision to send $1.6 billion to Novavax was not made simply because Novavax is a small company. And it was not made just because management has friendly relations with CEPI.  

The simplest explanation is probably the best one. The federal government really wants a working COVID-19 vaccine. This is why it's granting such high dollar amounts in the first place. And science doesn't play favorites. Novavax was selected for a $1.6 billion grant not because it's a small company or enjoys favoritism. Novavax won that grant because its animal data is the most promising of all the vaccine candidates to date. 

Back in June, Novavax announced its animal data for its vaccine candidate, NVX-CoV2373.  "We are seeing neutralizing titers in the 10,000 range in nonhuman primates," said Dr. Gregory Glenn, the head of research and development at Novavax. Other companies are reporting antibody data in the 40 to 200 range in animal testing.

As a point of contrast, earlier this month Pfizer and its partner, BioNTech (BNTX 1.11%), announced that in a phase 1 trial, 10 micrograms of its vaccine candidate produced an average of 168 antibodies in humans, while a dose of 30 micrograms yielded 267.

While Novavax has not released its phase 1 data as applies to humans yet, a vaccine candidate that produces 10,000 antibodies in primates is very impressive. It's likely why the company was awarded almost $2 billion in grant funding.

We're anxious to see whether this impressive result in animal testing can be reproduced in humans.


Taylor Carmichael owns shares of Novavax. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$41.47 (2.80%) $1.13
Pfizer Inc. Stock Quote
Pfizer Inc.
$50.11 (3.77%) $1.82
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$91.02 (2.35%) $2.09
Johnson & Johnson Stock Quote
Johnson & Johnson
$165.30 (-1.10%) $-1.84
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.64 (3.08%) $1.99
Moderna, Inc. Stock Quote
Moderna, Inc.
$171.18 (-0.37%) $0.63
BioNTech SE Stock Quote
BioNTech SE
$160.35 (1.11%) $1.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.